These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25444398)

  • 1. Investment in pneumonia and pneumococcal research.
    Head MG; Fitchett JR; Newell ML; Scott JAG; Clarke SC; Atun R
    Lancet Infect Dis; 2014 Nov; 14(11):1037-1038. PubMed ID: 25444398
    [No Abstract]   [Full Text] [Related]  

  • 2. Investment in antibiotics against pneumonia.
    Fernandes P
    Lancet Infect Dis; 2015 Apr; 15(4):376. PubMed ID: 25809890
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges in mapping research investments for treatments against pneumonia.
    Head MG; Fitchett JR; Clarke SC
    Lancet Infect Dis; 2015 Nov; 15(11):1262. PubMed ID: 26531036
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of the US priority review voucher on private-sector investment in global health research and development.
    Robertson AS; Stefanakis R; Joseph D; Moree M
    PLoS Negl Trop Dis; 2012; 6(8):e1750. PubMed ID: 22953004
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues and challenges: pneumococcal vaccination in pediatrics.
    Black S; Shinefield H
    Pediatr Ann; 1997 Jun; 26(6):355-60. PubMed ID: 9188126
    [No Abstract]   [Full Text] [Related]  

  • 6. A new market to save lives from pneumococcal disease.
    Lancet Infect Dis; 2011 Feb; 11(2):73. PubMed ID: 21272785
    [No Abstract]   [Full Text] [Related]  

  • 7. Global epidemiology of pneumococcal disease--new prospects for vaccine control.
    Antao VC; Hausdorff WP
    Adv Exp Med Biol; 2009; 634():19-29. PubMed ID: 19280845
    [No Abstract]   [Full Text] [Related]  

  • 8. New pneumococcal vaccines for children.
    Choo S; Finn A
    Arch Dis Child; 2001 Apr; 84(4):289-94. PubMed ID: 11259222
    [No Abstract]   [Full Text] [Related]  

  • 9. The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in development.
    Vyse A; Campling J; Czudek C; Ellsbury G; Slack M
    Vaccine; 2020 Dec; 38(51):8068-8070. PubMed ID: 33190949
    [No Abstract]   [Full Text] [Related]  

  • 10. Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine.
    Elemraid MA; Sails AD; Eltringham GJ; Perry JD; Rushton SP; Spencer DA; Thomas MF; Eastham KM; Hampton F; Gennery AR; Clark JE;
    Eur Respir J; 2013 Dec; 42(6):1595-603. PubMed ID: 23598951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England.
    Saxena S; Atchison C; Cecil E; Sharland M; Koshy E; Bottle A
    J Infect; 2015 Oct; 71(4):428-36. PubMed ID: 26159503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping pneumonia research: A systematic analysis of UK investments and published outputs 1997-2013.
    Head MG; Fitchett JR; Newell ML; Scott JA; Harris JN; Clarke SC; Atun R
    EBioMedicine; 2015 Sep; 2(9):1193-9. PubMed ID: 26501117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expected benefits of pneumococcal vaccination in Canadian infants and children < 5 years old.
    Can Commun Dis Rep; 2006 Mar; 32(5):45-54. PubMed ID: 16649291
    [No Abstract]   [Full Text] [Related]  

  • 14. EpiReview: invasive pneumococcal disease, NSW, 2002.
    Gilmour R
    N S W Public Health Bull; 2005; 16(1-2):26-30. PubMed ID: 16106285
    [No Abstract]   [Full Text] [Related]  

  • 15. A preventable killer: Pneumonia.
    Klugman KP; ; Garau J;
    Clin Microbiol Infect; 2009 Nov; 15(11):989-90. PubMed ID: 19874383
    [No Abstract]   [Full Text] [Related]  

  • 16. Market watch: Evolution of Chinese bioclusters as a framework for investment policies in emerging markets.
    Gautam A
    Nat Rev Drug Discov; 2015 Jan; 14(1):8. PubMed ID: 25503337
    [No Abstract]   [Full Text] [Related]  

  • 17. Pneumococcal pneumonia in hospitalized Uruguayan children and potential prevention with different vaccine formulations.
    Hortal M; Sehabiague G; Camou T; Iraola I; Estevan M; Pujadas M
    J Pediatr; 2008 Jun; 152(6):850-3. PubMed ID: 18492530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.
    Grijalva CG; Nuorti JP; Arbogast PG; Martin SW; Edwards KM; Griffin MR
    Lancet; 2007 Apr; 369(9568):1179-86. PubMed ID: 17416262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Have you 'herd'? Childhood pneumonia immunization has long-lasting impact on populations.
    Rees J
    Expert Rev Vaccines; 2013 Sep; 12(9):985-6. PubMed ID: 24053392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.